Prosecution Insights
Last updated: October 01, 2026

Examiner: VOKES, KATHLEEN PAIGE

Tech Center 3700 • Art Units: 3783

This examiner grants 55% of resolved cases

Analysis

Kathleen Paige Vokes works in Tech Center 3700 and Art Unit 3783. The examiner has 78 resolved cases. The allowance rate is 55.1 percent. This suggests that a moderate portion of the applications reaching a resolution are granted. Practitioners should prepare for a balanced examination process when assigned to this examiner in Art Unit 3783.

The interview lift is 25.9 percent. This positive lift indicates that interviews are an effective tool for increasing the 55.1 percent allowance rate. Practitioners should consider this as a primary strategy for resolving issues and advancing the application toward a grant. The data shows that direct communication can be a significant factor in overcoming rejections.

The median days to allowance is 1499. This is a relatively long pendency for applications that result in a grant. With 78 resolved cases, the data provides a baseline for expectations when prosecuting applications before this examiner in Tech Center 3700. This timeline is an important factor for applicants to consider when planning their patent strategy.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

55.1%
Allow Rate
-14.9% vs TC avg
122
Total Applications
+25.9%
Interview Lift
1499
Avg Prosecution Days
Based on 78 resolved cases, 2023–2026

Rejection Statute Breakdown

0.9%
§101 Eligibility
21.0%
§102 Novelty
56.9%
§103 Obviousness
18.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
16983212 MULTI-UNIT DRUG DELIVERY DEVICES AND METHODS Non-Final OA Janssen Biotech, Inc.
18114080 SINGLE CAVITY HEMOSTASIS VALVE HUB FOR INTRODUCER SHEATHS Non-Final OA Boston Scientific Scimed Inc.
17889329 DEVICES, SYSTEMS, AND METHODS FOR ACTIVATION OF A PHOTOACTIVE AGENT Non-Final OA BOSTON SCIENTIFIC SCIMED, INC.
17185685 MEDICAL THERAPY SYSTEMS AND METHODS OF USING THE SAME Final Rejection Boston Scientific Scimed, Inc.
18383814 Rapidly Insertable Central Catheters Including Catheter Assemblies and Methods Thereof Final Rejection Bard Access Systems, Inc.
18098052 Reinforced Catheter Tips, Catheters, and Methods Thereof Final Rejection Bard Access Systems, Inc.
18891664 OPTIMIZED CATHETER SHEATH FOR RX CATHETER Non-Final OA CANON U.S.A., INC.
18884634 INFUSION DELIVERY DEVICE Non-Final OA Roche Diabetes Care, Inc.
16968134 INJECTOR AND METHOD OF INJECTING SOLUTION CONTAINING BIOMOLECULES INTO CELL NUCLEUS OF INJECTION TARGET USING THE SAME Non-Final OA DAICEL CORPORATION
18639864 WEARABLE BIOELECTRONICS FOR PROGRAMMABLE DELIVERY OF THERAPY Non-Final OA The Regents of the University of California
17130846 PROCESSOR-CONTROLLED PUMP IN IRRIGATION LINE OF PHACOEMULSIFICATION PROBE Final Rejection JOHNSON & JOHNSON SURGICAL VISION, INC.
17639940 MEDICAL CONNECTOR WITH AUTOMATIC SEALING ON DISCONNECTION Non-Final OA Fresenius Medical Care Deutschland GmBH
18455004 Injection Needle with Surface Texture Modification and Method of Manufacturing Thereof Final Rejection Becton, Dickinson and Company
17339505 COILED VASCULAR ACCESS INSTRUMENT AND RELATED SYSTEMS AND METHODS Final Rejection Becton, Dickinson and Company
17050321 DELIVERY DEVICE AND ADSORBENT Non-Final OA Becton, Dickinson and Company
18038748 Drug Delivery Device Final Rejection Sanofi
18469706 Needle Arrangement Final Rejection Sanofi-Aventis Deutschland GMBH
18455747 CATHETER ASSEMBLY Final Rejection TERUMO KABUSHIKI KAISHA
18883710 ADHESIVE PATCH AND SYSTEM FOR WEARABLE MEDICAL DEVICE Non-Final OA INSULET CORPORATION
18337683 METHODS AND SYSTEMS FOR OPTICAL-BASED FLUID CONTROL IN A FLUID DELIVERY SYSTEM Final Rejection INSULET CORPORATION

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month